Long-acting beta(2) agonists as potential option in the treatment of acute exacerbations of COPD

Pulm Pharmacol Ther. 2003;16(4):197-201. doi: 10.1016/S1094-5539(03)00025-7.
No abstract available

Publication types

  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Adrenergic beta-Agonists / pharmacokinetics
  • Adrenergic beta-Agonists / therapeutic use*
  • Airway Obstruction / drug therapy*
  • Airway Obstruction / etiology
  • Albuterol / analogs & derivatives*
  • Albuterol / pharmacokinetics
  • Albuterol / therapeutic use*
  • Bronchodilator Agents / pharmacokinetics
  • Bronchodilator Agents / therapeutic use*
  • Dose-Response Relationship, Drug
  • Ethanolamines / pharmacokinetics
  • Ethanolamines / therapeutic use*
  • Formoterol Fumarate
  • Half-Life
  • Humans
  • Pulmonary Disease, Chronic Obstructive / complications
  • Pulmonary Disease, Chronic Obstructive / drug therapy*
  • Pulmonary Disease, Chronic Obstructive / physiopathology
  • Salmeterol Xinafoate

Substances

  • Adrenergic beta-Agonists
  • Bronchodilator Agents
  • Ethanolamines
  • Salmeterol Xinafoate
  • Albuterol
  • Formoterol Fumarate